NCT06651021 - A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

October 28, 2024

Study Completion Date

October 28, 2024

Conditions

Healthy Volunteer

Interventions

DRUG

balcinrenone/dapagliflozin

"Each participant will receive a single dose of balcinrenone/dapagliflozin 40 mg/10 mg capsule on Day 1 under fasted condition.~Each participant will be involved in the study for up to 35 days."

Trial Locations (1)

610041

Research Site, Chengdu